Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doripenem versus cefepime in hospitalized children with suspected bacterial pneumonia
2009-016069-27Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bacterial pneumonia, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 1 more comparing Doripenem arm with Cefepime arm (2 arms). Primary endpoint: Changes in adverse events. Started Mar 2010; status: terminated.
02
Drugs
doripenemcefepime
03
Conditions
bacterial pneumoniahospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2009-016069-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016069-27.